PMID- 35033866
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20230202
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Print)
IS  - 0305-7372 (Linking)
VI  - 103
DP  - 2022 Feb
TI  - Management of adverse events associated with cabozantinib plus nivolumab in renal 
      cell carcinoma: A review.
PG  - 102333
LID - S0305-7372(21)00181-X [pii]
LID - 10.1016/j.ctrv.2021.102333 [doi]
AB  - Tyrosine kinase inhibitors have been successfully developed in combination with 
      immune checkpoint inhibitors to treat advanced renal cell carcinoma (RCC), 
      further advancing treatment. While safety profiles are generally manageable with 
      combination regimens, overlapping adverse events (AEs) and immune-related AEs can 
      make treatment more complex. The CheckMate 9ER study evaluated the tyrosine 
      kinase inhibitor cabozantinib in combination with the anti-programmed cell death 
      protein-1 antibody nivolumab in patients with previously untreated advanced RCC. 
      Cabozantinib + nivolumab demonstrated superiority over sunitinib for 
      progression-free survival, overall survival, and objective response rate. These 
      outcomes supported the approval of cabozantinib + nivolumab as a first-line 
      therapy for advanced RCC. The safety profile was manageable with prophylaxis, 
      supportive care, dose holds and reductions for cabozantinib, and dose holds and 
      immunosuppressive therapy for nivolumab. This review discusses the safety results 
      of CheckMate 9ER and provides guidance on managing some of the more clinically 
      relevant AEs with a focus on overlapping AEs, including diarrhea, elevated 
      amylase/lipase, hepatotoxicity, dermatologic reactions, fatigue, endocrine 
      disorders, and nephrotoxicity. We discuss AE management strategies (prophylaxis, 
      supportive care, dose modification, and immunosuppressive therapy), and provide 
      recommendations for identifying the causative agent of overlapping AEs and for 
      consulting specialists about organ-specific immune-related AEs. Optimizing AE 
      management can maintain tolerability and should be a priority with 
      cabozantinib + nivolumab treatment.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - McGregor, Bradley
AU  - McGregor B
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
FAU - Mortazavi, Amir
AU  - Mortazavi A
AD  - Division of Medical Oncology, Department of Internal Medicine, College of 
      Medicine, The Ohio State University, and the Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Cordes, Lisa
AU  - Cordes L
AD  - National Cancer Institute and the Office of Clinical Research at the National 
      Institutes of Health, Bethesda, MD, USA.
FAU - Salabao, Cristina
AU  - Salabao C
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
FAU - Vandlik, Susan
AU  - Vandlik S
AD  - The Ohio State University Wexner Medical Center and the Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Apolo, Andrea B
AU  - Apolo AB
AD  - Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. 
      Electronic address: andrea.apolo@nih.gov.
LA  - eng
GR  - ZIA BC011351/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC011594/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20211224
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Anilides)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Anilides/administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Clinical Trials as Topic
MH  - Diarrhea/chemically induced
MH  - Endocrine System Diseases/chemically induced
MH  - Exanthema/chemically induced
MH  - Fatigue/chemically induced
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Nivolumab/administration & dosage/adverse effects
MH  - Pyridines/administration & dosage/adverse effects
PMC - PMC9590624
MID - NIHMS1773878
OTO - NOTNLM
OT  - Advanced renal cell carcinoma
OT  - Adverse event management
OT  - Cabozantinib
OT  - CheckMate 9ER
OT  - Nivolumab
EDAT- 2022/01/17 06:00
MHDA- 2022/01/28 06:00
PMCR- 2023/02/01
CRDT- 2022/01/16 20:58
PHST- 2021/11/11 00:00 [received]
PHST- 2021/12/16 00:00 [revised]
PHST- 2021/12/20 00:00 [accepted]
PHST- 2022/01/17 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2022/01/16 20:58 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - S0305-7372(21)00181-X [pii]
AID - 10.1016/j.ctrv.2021.102333 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2022 Feb;103:102333. doi: 10.1016/j.ctrv.2021.102333. Epub 2021 
      Dec 24.